Results 241 to 250 of about 332,330 (302)

Fecal Calprotectin as a biomarker for early diagnosis and prediction of steroid response in Acute Gastrointestinal Graft versus Host Disease. [PDF]

Blood Cell Ther
Kumar SE, Selvarajan S, Varghese T, Bharadwaj PK, Lakshmi KS, Hanmantgad S, Dutta AK, Joseph AJ, Mathews V, George B.   +9 more
europepmc   +1 more source

Predictive Value of Nutrition Indices in Advanced Hepatocellular Carcinoma Patients Treated With Lenvatinib

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT The prognostic nutritional index (PNI) and geriatric nutritional risk index (GNRI) are simple markers that reflect immune and nutritional status. This retrospective study evaluated their prognostic significance in 276 patients with advanced hepatocellular carcinoma (HCC) who received first‐line lenvatinib. PNI and GNRI were calculated based on
Cheng‐Wei Kuo, Wei‐Chen Tai, Yen‐Hao Chen, Ming‐Chao Tsai, Jing‐Houng Wang, Sheng‐Nan Lu, Tsung‐Hui Hu, Chao‐Hung Hung, Chien‐Hung Chen, Yuan‐Hung Kuo   +9 more
wiley   +1 more source

Role of neutropenic diet in prevention of infection and graft-versus-host disease in haematopoietic stem cell transplant recipients: systematic review and meta-analysis protocol. [PDF]

Front Nutr
Maji M, Mandal S, Dhali A, Miller LJ, Grove J, Snowden JA, Chakrabarti S, Aithal G.   +7 more
europepmc   +1 more source

The Effect of Post-Transplant Cyclophosphamide Administration on Graft-Versus-Host Disease in Allogeneic Bone Marrow Transplantation. [PDF]

Cancers (Basel)
Kahraman S, Ozdemir E.
europepmc   +1 more source

Evolving Paradigms in Chronic Graft-Versus-Host Disease: From Global Immunosuppression to Precision Targeted and Cell-Based Therapies. [PDF]

Stem Cell Rev Rep
Wang Y, Liu W, Huang X, Xiao Y.
europepmc   +1 more source

Ixazomib decreases the risk of chronic graft-versus-host disease: identification of cGVHD biomarkers. [PDF]

Blood Adv
Caballero-Velázquez T, Delgado Serrano J, López-Corral L, Ferra-Coll C, García-Calderón CB, Valcárcel D, García-Cadenas I, Pérez López E, Jiménez Lorenzo MJ, Martín-Domínguez FM, Jiménez-León MLR, Orti G, Escamilla Gómez V, Blázquez-Goñi C, Cabero Martínez A, Andrade Ruiz H, Menéndez-Pedregal E, Sánchez-Guijo F, Pérez Simón JA.   +18 more
europepmc   +1 more source

Phase 1/2 trials of donor regulatory T cells for the treatment of steroid-refractory chronic graft-versus-host disease. [PDF]

Blood Adv
Soares MVD, Gómez VE, Azevedo RI, Pereira PNG, Velázquez TC, Mendes L, Alho AC, García-Guerrero E, Garcia-Calderón CB, Tharmaratnam K, Cabral IA, Ribeiro AC, Juncal C, Roncon S, Pais AT, Gil AR, Espada E, Rodrigues A, Garção A, Yaspo ML, Warnatz HJ, Lehrach H, Ward L, Barbosa-Morais NL, Quintas AM, Palmela P, Caldas C, Ferreira R, Leite L, Martins C, Lourenço F, Moreno R, Campilho F, Cheyne CP, Garcia-Fiñana M, Campos A, Baron F, Arpinati M, Hoffmann P, Edinger M, Koreth J, Ritz J, Vaz CP, Perez-Simon JA, Lacerda JF.   +44 more
europepmc   +1 more source

Low Dose of IL-2 Application for Graft-Versus-Host Disease Prophylaxis Following Haploidentical Stem Cell Transplantation. [PDF]

MedComm (2020)
Xu ZL, Lv M, Yu XX, Ding YY, Han TT, Fu HX, Zhang YY, Mo XD, Sun YQ, Xu LP, Zhang XH, Wang Y, Huang XJ, Zhao XY.   +13 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Graft-versus-Host Disease

New England Journal of Medicine, 1991
Graft-versus-host disease, both acute and chronic, continues to be the major complication of human bone marrow transplantation. Improved posttransplant chemoprophylaxis has reduced the incidence of acute graft-versus-host disease, but the incidence of the chronic form of the disease remains unchanged.
J L, Ferrara, H J, Deeg
openaire   +4 more sources